At a glance
| Product | Somavert |
|---|---|
| Action | GH receptor antagonist |
| Use | Acromegaly |
| Route | Subcutaneous injection |
| Primary biochemical marker | IGF-1 |
Overview
Somavert is used in acromegaly when surgery or radiotherapy has been inadequate or is unsuitable. The medicine acts outside the pituitary by blocking GH receptors in target tissues, so it can reduce IGF-1 even when GH secretion remains elevated. That distinction explains why biochemical monitoring differs from treatment that suppresses hormone release. Pegvisomant does not directly remove a pituitary tumor, and ongoing assessment of the underlying lesion remains part of care. It is not a peptide for increasing growth, athletic performance or muscle mass; its intended action is to oppose excessive GH signaling.
How it works
Pegvisomant is an engineered GH analog with polyethylene-glycol modification that binds the GH receptor without producing normal receptor activation. It competitively blocks endogenous GH signaling, reducing hepatic and tissue responses including IGF-1 production. This may improve insulin sensitivity in patients with GH excess. Standard GH measurements can be misleading during treatment because pegvisomant may interfere with assays and does not suppress secretion in the same way as pituitary-directed drugs.
Where it fits in acromegaly care
The label covers patients with inadequate response to surgery or radiation, or for whom these treatments are inappropriate. The goal is normalization of IGF-1, rather than use for nonspecific symptoms attributed to hormone imbalance.
Supporting sources [1]
Receptor-blockade efficacy
A randomized trial demonstrated dose-related reduction and normalization of IGF-1 in acromegaly. This established the ability to block peripheral GH effects, a different therapeutic strategy from inhibiting GH secretion at the pituitary.
Supporting sources [2]
Liver and injection-site effects
Liver enzyme elevations and liver injury require attention to label-based monitoring. Systemic hypersensitivity and injection-site changes, including lipohypertrophy, can occur. Improved insulin sensitivity may increase hypoglycemia risk in patients receiving glucose-lowering medicines.
Supporting sources [1]
Why GH is not the response target
The label directs assessment using IGF-1. GH assay interference and ongoing endogenous GH secretion make GH concentration unsuitable as the sole efficacy marker. Monitoring of pituitary tumor size remains relevant because receptor blockade is not direct tumor removal.
Supporting sources [1]
Opposite direction from GH replacement
Somatropin supplies GH activity, while pegvisomant blocks it. Their structural relationship does not imply similar therapeutic goals. A peptide catalog should preserve that opposite action rather than grouping both under an undifferentiated growth-hormone benefit.
Supporting sources [1]
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: PEGylated growth-hormone receptor antagonist protein.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DailyMed: Somavert prescribing information ↗Regulatory source · Checked 2026-10-27
- Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. ↗Original research · Checked 2026-10-27